Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Shire and Janssen seek approval for galantamine in the U.S.

Oct. 1, 1999

NeoTherapeutics initiates second phase IIb clinical trial of Neotrofin

Sep. 30, 1999

Gliatech commences product development program for schizophrenia and dementia

Sep. 30, 1999

Ondansetron effectively controls tardive dyskinesia and improves symptoms of psychosis

Sep. 29, 1999

Duloxetine safety and pharmacokinetics determined in healthy volunteers

Sep. 29, 1999

More brain GABA-A receptor ligands in the Neurogen pipeline

Sep. 29, 1999

Orally active, non-neurotoxic anticonvulsants and EAA antagonists designed by K & K Biosciences

Sep. 29, 1999

Calcium channel blockers described in recently issued patent by Warner-Lambert

Sep. 29, 1999

Novartis receives approvable letter from FDA for Trileptal

Sep. 29, 1999

Neurogen's new brain GABA-A receptor ligands presented in patent literature

Sep. 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.